Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Nov 3

PMID 27806072

Citations 11

Authors

Jing Zhou

Li He

Ping Liu

Hui Duan

Hanze Zhang

Weili Li

Shipeng Gong

Guidong Su

Chunlin Chen

Affiliations

Soon will be listed here.

Abstract

Purpose: To study the therapeutic effects of uterine artery embolization (UAE) on adenomyosis and to investigate the association between uterine blood supply and artery embolization treatment outcomes.

Methods: Using digital subtraction angiography (DSA) imaging data, we retrospectively evaluated the vascular features of 252 adenomyosis patients treated with UAE. The cases were classified based on the equality of uterine blood supply (equal and unequal subgroups) and the degree of vascularity at the adenomyosis lesion site (hypervascular, isovascular and hypovascular subgroups). Patients were followed-up for 5 years after UAE. Improvements in dysmenorrhea and menorrhagia were evaluated based on the relief of the patients' symptoms. The improvement rates among the different subgroups were analyzed and compared.

Results: The improvement rates of dysmenorrhea and menorrhagia were 74.0% and 70.9%, respectively, at the short-term (12-month) follow-up and 70.4% and 68.8%, respectively, at the long-term (5-year) follow-up. No statistically significant differences were observed in the improvement rates for dysmenorrhea or menorrhagia between the equal and unequal blood supply subgroups at either the short- or long-term follow-up. The improvement rates for dysmenorrhea among the hypervascular, isovascular and hypovascular subgroups were 86.5%, 71.8% and 58.8%, respectively, at the short-term follow-up (p = 0.002) and 83.6%, 67.3% and 52.8%, respectively, at the long-term follow-up (p = 0.005). The improvement rates for menorrhagia in the hypervascular, isovascular and hypovascular subgroups were 81.0%, 68.3% and 60.7%, respectively, at the short-term follow-up (p = 0.024) and 79.4%, 61.4% and 62.2%, respectively, at the long-term follow-up (p = 0.052).

Conclusion: UAE is effective in treating patients with adenomyosis in both the short and long term. The outcomes of patients with adenomyosis were significantly correlated with lesion vascularity.

Citing Articles

Adenomyosis: An Update Concerning Diagnosis, Treatment, and Fertility.

Selntigia A, Molinaro P, Tartaglia S, Pellicer A, Galliano D, Cozzolino M J Clin Med. 2024; 13(17).

PMID: 39274438 PMC: 11396652. DOI: 10.3390/jcm13175224.

Adenomyosis and Abnormal Uterine Bleeding: Review of the Evidence.

Habiba M, Guo S, Benagiano G Biomolecules. 2024; 14(6).

PMID: 38927019 PMC: 11201750. DOI: 10.3390/biom14060616.

The Asian Society of Endometriosis and Adenomyosis guidelines for managing adenomyosis.

Harada T, Taniguchi F, Guo S, Choi Y, Biberoglu K, Tsai S Reprod Med Biol. 2023; 22(1):e12535.

PMID: 37701076 PMC: 10493363. DOI: 10.1002/rmb2.12535.

A Systematic Review and Meta-Analysis of the Efficacy of Uterine Artery Embolization in the Treatment of Endometriosis.

Ma L, Wen B, Wen Z Comput Intell Neurosci. 2022; 2022:8966063.

PMID: 36248948 PMC: 9553446. DOI: 10.1155/2022/8966063.

Adenomyosis - An Overview.

Wong S, Ray Jr C Semin Intervent Radiol. 2022; 39(1):119-122.

PMID: 35210742 PMC: 8856779. DOI: 10.1055/s-0042-1742345.

References

Kim M, Kim Y, Kim H, Cho J, Kang H, Lee C . Uterine artery embolization for symptomatic adenomyosis: a new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes. J Vasc Interv Radiol. 2011; 22(4):497-502. DOI: 10.1016/j.jvir.2011.01.426. View

Toh C, Wu C, Tsay P, Yeow K, Pan K, Tseng J . Uterine artery embolization for symptomatic uterine leiomyoma and adenomyosis. J Formos Med Assoc. 2003; 102(10):701-6. View

Bratby M, Walker W . Uterine artery embolisation for symptomatic adenomyosis--mid-term results. Eur J Radiol. 2008; 70(1):128-32. DOI: 10.1016/j.ejrad.2007.12.009. View

Lohle P, de Vries J, Klazen C, Boekkooi P, Vervest H, Smeets A . Uterine artery embolization for symptomatic adenomyosis with or without uterine leiomyomas with the use of calibrated tris-acryl gelatin microspheres: midterm clinical and MR imaging follow-up. J Vasc Interv Radiol. 2007; 18(7):835-41. DOI: 10.1016/j.jvir.2007.04.024. View

Kitamura Y, Allison S, Jha R, Spies J, Flick P, Ascher S . MRI of adenomyosis: changes with uterine artery embolization. AJR Am J Roentgenol. 2006; 186(3):855-64. DOI: 10.2214/AJR.04.1661. View

Streuli I, Dubuisson J, Santulli P, de Ziegler D, Batteux F, Chapron C . An update on the pharmacological management of adenomyosis. Expert Opin Pharmacother. 2014; 15(16):2347-60. DOI: 10.1517/14656566.2014.953055. View

Jang D, Kim M, Lee S, Kim I, Park S, Won J . The effect of uterine artery embolization on premenstrual symptoms in patients with symptomatic fibroids or adenomyosis. J Vasc Interv Radiol. 2014; 25(6):833-838.e1. DOI: 10.1016/j.jvir.2014.01.036. View

Liang E, Brown B, Kirsop R, Stewart P, Stuart A . Efficacy of uterine artery embolisation for treatment of symptomatic fibroids and adenomyosis - an interim report on an Australian experience. Aust N Z J Obstet Gynaecol. 2012; 52(2):106-12. DOI: 10.1111/j.1479-828X.2011.01399.x. View

Smeets A, Nijenhuis R, Boekkooi P, Vervest H, van Rooij W, Lohle P . Long-term follow-up of uterine artery embolization for symptomatic adenomyosis. Cardiovasc Intervent Radiol. 2011; 35(4):815-9. DOI: 10.1007/s00270-011-0203-1. View

10.

Bae S, Kim M, Kim G, Lee S, Park S, Won J . Uterine Artery Embolization for Adenomyosis: Percentage of Necrosis Predicts Midterm Clinical Recurrence. J Vasc Interv Radiol. 2015; 26(9):1290-6.e2. DOI: 10.1016/j.jvir.2015.04.026. View

11.

Nijenhuis R, Smeets A, Morpurgo M, Boekkooi P, Reuwer P, Smink M . Uterine artery embolisation for symptomatic adenomyosis with polyzene F-coated hydrogel microspheres: three-year clinical follow-up using UFS-QoL questionnaire. Cardiovasc Intervent Radiol. 2014; 38(1):65-71. DOI: 10.1007/s00270-014-0878-1. View

12.

Froeling V, Scheurig-Muenkler C, Hamm B, Kroencke T . Uterine artery embolization to treat uterine adenomyosis with or without uterine leiomyomata: results of symptom control and health-related quality of life 40 months after treatment. Cardiovasc Intervent Radiol. 2011; 35(3):523-9. DOI: 10.1007/s00270-011-0254-3. View

13.

Jung D, Kim M, Oh Y, Won J, Lee D . Prediction of early response to uterine arterial embolisation of adenomyosis: value of T2 signal intensity ratio of adenomyosis. Eur Radiol. 2012; 22(9):2044-9. DOI: 10.1007/s00330-012-2436-z. View

14.

Siskin G, Tublin M, Stainken B, Dowling K, Dolen E . Uterine artery embolization for the treatment of adenomyosis: clinical response and evaluation with MR imaging. AJR Am J Roentgenol. 2001; 177(2):297-302. DOI: 10.2214/ajr.177.2.1770297. View

15.

Taran F, Stewart E, Brucker S . Adenomyosis: Epidemiology, Risk Factors, Clinical Phenotype and Surgical and Interventional Alternatives to Hysterectomy. Geburtshilfe Frauenheilkd. 2014; 73(9):924-931. PMC: 3859152. DOI: 10.1055/s-0033-1350840. View

16.

Popovic M, Puchner S, Berzaczy D, Lammer J, Bucek R . Uterine artery embolization for the treatment of adenomyosis: a review. J Vasc Interv Radiol. 2011; 22(7):901-9. DOI: 10.1016/j.jvir.2011.03.013. View

17.

Levgur M . Therapeutic options for adenomyosis: a review. Arch Gynecol Obstet. 2006; 276(1):1-15. DOI: 10.1007/s00404-006-0299-8. View

18.

Smith B, Penny K, Purves A, Munro C, Wilson B, Grimshaw J . The Chronic Pain Grade questionnaire: validation and reliability in postal research. Pain. 1997; 71(2):141-7. DOI: 10.1016/s0304-3959(97)03347-2. View

19.

Kim M, Kim S, Kim N, Lee M, Ahn E, Kim H . Long-term results of uterine artery embolization for symptomatic adenomyosis. AJR Am J Roentgenol. 2006; 188(1):176-81. DOI: 10.2214/AJR.05.1613. View